Loading...
Ulcerative STDs have long been linked to increased risk for HIV transmission. Daily suppressive valacyclovir has been shown to reduce virologic shedding and the incidence of disease recurrence. Dr. Larry Corey and colleagues presented the results of a 4-year, randomized, double-blind, prospective, placebo-controlled international trial of valacyclovir, 500 mg once daily for 8 months, aimed at preventing transmission of genital herpes.
Monogamous heterosexual couples serodiscordant for herpes were enrolled, and condoms and safe sex counseling were provided at each study visit. The primary endpoint was the proportion of susceptible partners with a first episode of symptomatic genital herpes. Among 1484 herpes simplex virus-2-discordant couples…